Inventiva S.A. ADR (IVA)

$4.00 +0.18 (4.71%)
Market Cap 531.56M
Revenue (ttm) 15.93M
Net Income (ttm) -199.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,251.35%
Debt to Equity Ratio -6.42
Volume 226,700
Avg Vol 252,444
Day's Range N/A - N/A
Shares Out 139.15M
Stochastic %K 53%
Beta 0.68
Analysts Strong Sell
Price Target $15.55

Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 3 80 44 75 00
Address:
50 rue de Dijon, Daix, France
DonCorleone77
DonCorleone77 Nov. 13 at 2:38 PM
$IVA Inventiva 32.47M share Spot Secondary priced at $3.85
0 · Reply
Toptradersam
Toptradersam Nov. 13 at 1:08 PM
$SPY $IVA $CLBT $MRSN $SEE Know this ASAP! 🚨🚨 https://www.youtube.com/watch?v=qaM4xfqi2BQ
0 · Reply
twincam
twincam Nov. 10 at 11:29 PM
$GPCR $NVO $NVO’s next M&A wave likely targets small-cap metabolic names it can absorb fast 👀 🧩 $GPCR — oral GLP-1, sweet spot ~$2-4B 💊 $IVA — late-stage MASH, ~$1B w/ CVR 🧬 $GNFT — liver bolt-on <$0.5B 🐍 $ZEAL — combo peptide giant $7-14B (too rich?) Smart money’s betting Novo reloads with bite-sized deals, not another bidding war.
0 · Reply
BioRich
BioRich Nov. 10 at 4:44 AM
$IVA Looks like the market is telling us they liked what they've seen from $IVA at AASLD. Not a surprise, but nice to see confirmation. Not so much for the snake oil. Their AASLD disaster looks like it's already getting Wall Streets attention. Congrats $IVA. Cheers!
1 · Reply
BioRich
BioRich Nov. 9 at 6:37 PM
$ALT Hope @Wolly99 takes the time to take a peak at the future of MASH and Fibrosis ($IVA). While ALTers focus on splicing hope, $IVA continues to chug along.
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 1:24 PM
Wolfe Research has updated their rating for Inventiva ( $IVA ) to Outperform with a price target of 13.
1 · Reply
Jonita
Jonita Nov. 4 at 12:06 PM
$IVA
0 · Reply
Casparov
Casparov Nov. 3 at 6:16 PM
$IVA Way undervalued
0 · Reply
BioRich
BioRich Nov. 1 at 7:16 PM
$ALT If you're looking for companies with legitimate fibrosis improvement, who also have impressive (and extensive) AI/NIT path forward, check out $IVA. 4 different presentations at AASLD.
2 · Reply
BioRich
BioRich Oct. 31 at 8:38 AM
$ALT As many are interested in sector moves on this board, you may have noticed the rapid drop in $IVA this week. They great news, and this is important to ALTers, it's that it appears the drop has nothing to do with company, drug, or investor sentiment, rather being the victim being held on 2 exchanges (which ultimately had a 110% share price discrepancy). $IVA is still a leader in many ways and i still believe ther get a deal done very soon. This multi-market correction may have been the final signal before finalizing the deal. Here's a helpful article to explain much better than i can: https://www.biostockinfo.com/adr_warning/
1 · Reply
Latest News on IVA
Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Nov 13, 2025, 10:25 AM EST - 1 day ago

Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares

Nov 13, 2025, 9:22 AM EST - 1 day ago

Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares

Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris

Nov 13, 2025, 2:40 AM EST - 1 day ago

Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris

Inventiva announces launch of public offering

Nov 12, 2025, 4:25 PM EST - 2 days ago

Inventiva announces launch of public offering

Inventiva Announces the Implementation of a New ATM Program

Oct 14, 2025, 4:00 PM EDT - 4 weeks ago

Inventiva Announces the Implementation of a New ATM Program

Inventiva S.A. (IVA) Analyst/Investor Day Transcript

Oct 8, 2025, 7:16 PM EDT - 5 weeks ago

Inventiva S.A. (IVA) Analyst/Investor Day Transcript

Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025

Oct 7, 2025, 4:00 PM EDT - 5 weeks ago

Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025

Inventiva Appoints Andrew Obenshain as Chief Executive Officer

Oct 1, 2025, 2:30 AM EDT - 6 weeks ago

Inventiva Appoints Andrew Obenshain as Chief Executive Officer

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Sep 29, 2025, 8:06 AM EDT - 6 weeks ago

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

MLTX

Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update

Sep 29, 2025, 2:30 AM EDT - 6 weeks ago

Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update

Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings

Sep 29, 2025, 2:26 AM EDT - 6 weeks ago

Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings

Inventiva to Host Analyst and Investor Event on October 8, 2025

Sep 24, 2025, 4:00 PM EDT - 7 weeks ago

Inventiva to Host Analyst and Investor Event on October 8, 2025

Inventiva to Participate in Upcoming September Investor Conferences

Sep 4, 2025, 4:00 PM EDT - 2 months ago

Inventiva to Participate in Upcoming September Investor Conferences

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Aug 11, 2025, 4:00 PM EDT - 3 months ago

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Jul 31, 2025, 4:00 PM EDT - 3 months ago

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

Jul 9, 2025, 4:05 PM EDT - 4 months ago

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

Inventiva receives $10 million milestone payment from CTTQ

Jul 7, 2025, 4:00 PM EDT - 4 months ago

Inventiva receives $10 million milestone payment from CTTQ

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

Jul 2, 2025, 4:00 PM EDT - 4 months ago

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 27, 2025, 4:00 PM EDT - 6 months ago

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025, 2:30 AM EDT - 6 months ago

Inventiva reports 2025 First Quarter Financial Information¹

Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

May 23, 2025, 2:00 AM EDT - 6 months ago

Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

May 5, 2025, 2:30 AM EDT - 6 months ago

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

Apr 30, 2025, 4:00 PM EDT - 7 months ago

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

Apr 24, 2025, 4:01 PM EDT - 7 months ago

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Apr 15, 2025, 4:00 PM EDT - 7 months ago

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Apr 1, 2025, 5:00 PM EDT - 8 months ago

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 10:50 AM EDT - 8 months ago

Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript

Inventiva reports its 2024 full year results and provides a business update

Mar 26, 2025, 4:00 PM EDT - 8 months ago

Inventiva reports its 2024 full year results and provides a business update

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Mar 19, 2025, 4:00 PM EDT - 8 months ago

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Feb 26, 2025, 4:00 PM EST - 9 months ago

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Feb 20, 2025, 4:00 PM EST - 9 months ago

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Feb 10, 2025, 4:00 PM EST - 9 months ago

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Jan 29, 2025, 4:00 PM EST - 10 months ago

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Jan 22, 2025, 4:00 PM EST - 10 months ago

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 4:00 PM EST - 11 months ago

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Dec 16, 2024, 2:30 AM EST - 11 months ago

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024

Dec 12, 2024, 4:00 PM EST - 1 year ago

Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024

Inventiva reports 2024 Third Quarter Financial Information¹

Nov 21, 2024, 4:00 PM EST - 1 year ago

Inventiva reports 2024 Third Quarter Financial Information¹

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Nov 20, 2024, 4:00 PM EST - 1 year ago

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams

Nov 18, 2024, 8:30 AM EST - 1 year ago

Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams

ALIT

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Nov 15, 2024, 4:00 PM EST - 1 year ago

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

Oct 30, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Oct 14, 2024, 1:45 PM EDT - 1 year ago

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

Oct 14, 2024, 10:48 AM EDT - 1 year ago

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

Oct 14, 2024, 2:35 AM EDT - 1 year ago

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Oct 14, 2024, 2:30 AM EDT - 1 year ago

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Sep 25, 2024, 4:00 PM EDT - 1 year ago

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Jul 31, 2024, 4:00 PM EDT - 1 year ago

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Jul 25, 2024, 4:00 PM EDT - 1 year ago

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

DonCorleone77
DonCorleone77 Nov. 13 at 2:38 PM
$IVA Inventiva 32.47M share Spot Secondary priced at $3.85
0 · Reply
Toptradersam
Toptradersam Nov. 13 at 1:08 PM
$SPY $IVA $CLBT $MRSN $SEE Know this ASAP! 🚨🚨 https://www.youtube.com/watch?v=qaM4xfqi2BQ
0 · Reply
twincam
twincam Nov. 10 at 11:29 PM
$GPCR $NVO $NVO’s next M&A wave likely targets small-cap metabolic names it can absorb fast 👀 🧩 $GPCR — oral GLP-1, sweet spot ~$2-4B 💊 $IVA — late-stage MASH, ~$1B w/ CVR 🧬 $GNFT — liver bolt-on <$0.5B 🐍 $ZEAL — combo peptide giant $7-14B (too rich?) Smart money’s betting Novo reloads with bite-sized deals, not another bidding war.
0 · Reply
BioRich
BioRich Nov. 10 at 4:44 AM
$IVA Looks like the market is telling us they liked what they've seen from $IVA at AASLD. Not a surprise, but nice to see confirmation. Not so much for the snake oil. Their AASLD disaster looks like it's already getting Wall Streets attention. Congrats $IVA. Cheers!
1 · Reply
BioRich
BioRich Nov. 9 at 6:37 PM
$ALT Hope @Wolly99 takes the time to take a peak at the future of MASH and Fibrosis ($IVA). While ALTers focus on splicing hope, $IVA continues to chug along.
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 1:24 PM
Wolfe Research has updated their rating for Inventiva ( $IVA ) to Outperform with a price target of 13.
1 · Reply
Jonita
Jonita Nov. 4 at 12:06 PM
$IVA
0 · Reply
Casparov
Casparov Nov. 3 at 6:16 PM
$IVA Way undervalued
0 · Reply
BioRich
BioRich Nov. 1 at 7:16 PM
$ALT If you're looking for companies with legitimate fibrosis improvement, who also have impressive (and extensive) AI/NIT path forward, check out $IVA. 4 different presentations at AASLD.
2 · Reply
BioRich
BioRich Oct. 31 at 8:38 AM
$ALT As many are interested in sector moves on this board, you may have noticed the rapid drop in $IVA this week. They great news, and this is important to ALTers, it's that it appears the drop has nothing to do with company, drug, or investor sentiment, rather being the victim being held on 2 exchanges (which ultimately had a 110% share price discrepancy). $IVA is still a leader in many ways and i still believe ther get a deal done very soon. This multi-market correction may have been the final signal before finalizing the deal. Here's a helpful article to explain much better than i can: https://www.biostockinfo.com/adr_warning/
1 · Reply
BioRich
BioRich Oct. 29 at 7:12 PM
$ALT Don't follow me. There's a strong potential you'll make money. Sold some $ALT this morning ~4.09, saving a 4% loss, and rolled it into $IVA for a 30+% gain. So let's see, that means my effective gain is 34%. Lazy money doesn't make money. And Congrats to @Diapers_Tequila for following my picks and getting $IVA on the radar. Hope you bought. Cheers!
0 · Reply
aletz
aletz Oct. 29 at 3:49 PM
$IVA https://www.biostockinfo.com/adr_warning/ My take on IVA's drop
1 · Reply
Bernardbaruch1
Bernardbaruch1 Oct. 29 at 3:47 PM
$IVA 100 million atm to raise capital is why the drop
1 · Reply
badarchitect
badarchitect Oct. 29 at 3:14 PM
$IVA warming up, run it
0 · Reply
BioRich
BioRich Oct. 29 at 2:59 PM
$IVA Insane buy opportunity here. Hope folks bought it lower and are still buying now. Should regain nicely. My favorite explanation for this drop was to ensure that they were able to close the deal (Buyout) at the SP they started the negotiations and not have to change the paperwork. Looking for AH news. If true, congrats $IVA Longs!!! $XBI
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 29 at 2:12 PM
$IVA just reversed 4% higher to -16% (~1Mv) a few minutes ago, follow for more volatility.
0 · Reply
UgoGreg
UgoGreg Oct. 29 at 1:55 PM
$IVA https://youtu.be/f9mvcJRGplU
0 · Reply
ejz92
ejz92 Oct. 29 at 1:10 PM
$IVA Any idea on cause of selloff? Haven’t seen any news.
1 · Reply
Pharmadesiguru
Pharmadesiguru Oct. 29 at 1:09 PM
$IVA look at the sec filing, dilution biggly to fatten pockets, backfiring
1 · Reply
TA_Kongen
TA_Kongen Oct. 29 at 12:26 PM
$IVA Been watching this but endless sellers. Something for sure going on but nothing official yet.
0 · Reply
bkfViking123
bkfViking123 Oct. 29 at 11:58 AM
$IVA i bought starters ... there is no news ... GROK
0 · Reply
BioRich
BioRich Oct. 28 at 8:01 PM
$IVA Bullish. Very, very Bullish. Hit the wrong tab.
0 · Reply